$ATIP
ATI Physical Therapy, Inc. Stock $atip

$atip Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000181584923000004 Filed on March 16, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$166.9M	$161.8M	$635.7M
YoY Change	8.52%	3.85%	1.24%
Cost Of Revenue	$143.6M	$139.8M	$560.6M
YoY Change	3.27%	2.87%	8.33%
Gross Profit	$23.35M	$21.98M	$75.12M
YoY Change	57.86%	10.55%	-31.98%
Gross Profit Margin	13.99%	13.59%	11.82%
Selling, General & Admin	$30.60M	$26.81M	$114.7M
YoY Change	1.9%	-10.34%	2.61%
% of Gross Profit	131.02%	121.95%	152.72%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$9.691M	$10.11M	$40.59M
YoY Change	-4.15%	1.08%	6.83%
% of Gross Profit	41.5%	46.01%	54.03%
Operating Expenses	$30.60M	$30.09M	$114.7M
YoY Change	1.9%	0.65%	2.61%
Operating Profit	-$11.37M	-$8.109M	-$539.7M
YoY Change	-93.54%	-33.05%	-44.93%
Interest Expense	-$13.94M	-$13.46M	-$45.28M
YoY Change	61.0%	86.6%	-19.73%
% of Operating Profit
Other Income/Expense, Net	-$354.0K	$10.21M	-$3.333M
YoY Change	-87.27%	-34.73%	1282.99%
Pretax Income	-$25.15M	-$107.4M	-$541.6M
YoY Change	-84.43%	2809.92%	-36.51%
Income Tax	$100.0K	-$4.998M	-$48.53M
% Of Pretax Income
Net Earnings	-$26.27M	-$102.8M	-$492.4M
YoY Change	-80.93%	-12617.05%	-36.74%
Net Earnings / Revenue	-15.74%	-63.53%	-77.46%
Basic Earnings Per Share	-$0.15		-$2.51
Diluted Earnings Per Share	-$0.15	-$0.50	-$2.51
COMMON SHARES
Basic Shares Outstanding	207.4M shares	207.3M shares	203.2M shares
Diluted Shares Outstanding	204.9M shares		203.2M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$63.08M	$83.14M	$83.14M
YoY Change	-33.46%	71.01%	71.01%
Cash & Equivalents	$63.08M	$83.10M
Short-Term Investments
Other Short-Term Assets	$6.722M	$10.04M	$30.32M
YoY Change	0.96%	213.36%	142.43%
Inventory
Prepaid Expenses	$9.373M	$13.53M
Receivables	$82.21M	$80.67M	$80.67M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$166.8M	$194.1M	$194.1M
YoY Change	-15.72%	35.21%	35.21%
LONG-TERM ASSETS
Property, Plant & Equipment	$119.5M	$123.7M	$349.8M
YoY Change	-12.63%	-11.48%	-11.76%
Goodwill	$286.5M	$286.5M
YoY Change	-41.81%	-52.95%
Intangibles	$246.4M	$246.6M
YoY Change	-33.78%	-40.11%
Long-Term Investments
YoY Change
Other Assets	$1.823M	$2.030M	$2.030M
YoY Change	-35.15%	-9.09%	-9.09%
Total Long-Term Assets	$878.9M	$884.9M	$884.9M
YoY Change	-30.21%	-37.65%	-37.65%
TOTAL ASSETS
Total Short-Term Assets	$166.8M	$194.1M	$194.1M
Total Long-Term Assets	$878.9M	$884.9M	$884.9M
Total Assets	$1.046B	$1.079B	$1.079B
YoY Change	-28.24%	-30.95%	-30.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.25M	$12.56M	$12.56M
YoY Change	-16.46%	-17.08%	-17.08%
Accrued Expenses	$94.50M	$95.19M	$95.19M
YoY Change	-7.93%	-9.44%	-9.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$111.2M	$116.5M	$116.5M
YoY Change	-9.06%	-15.15%	-15.15%
LONG-TERM LIABILITIES
Long-Term Debt	$534.1M	$531.6M	$531.6M
YoY Change	11.79%	-2.24%	-2.24%
Other Long-Term Liabilities	$1.821M	$1.834M	$223.2M
YoY Change	-22.44%	-20.3%	-26.24%
Total Long-Term Liabilities	$536.0M	$533.4M	$754.8M
YoY Change	11.62%	-2.32%	-10.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$111.2M	$116.5M	$116.5M
Total Long-Term Liabilities	$536.0M	$533.4M	$754.8M
Total Liabilities	$884.9M	$890.2M	$894.7M
YoY Change	-3.67%	-15.31%	-15.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.366B	-$1.340B
YoY Change	38.67%	58.12%
Common Stock	$20.00K	$20.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$100.0K
YoY Change		5.26%
Treasury Stock Shares		80.00K shares
Shareholders Equity	$15.64M	$43.96M	$184.3M
YoY Change
Total Liabilities & Shareholders Equity	$1.046B	$1.079B	$1.079B
YoY Change	-28.24%	-30.95%	-30.95%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$26.27M	-$102.8M	-$492.4M
YoY Change	-80.93%	-12617.05%	-36.74%
Depreciation, Depletion And Amortization	$9.691M	$10.11M	$40.59M
YoY Change	-4.15%	1.08%	6.83%
Cash From Operating Activities	-$14.20M	-$6.428M	-$65.50M
YoY Change	-46.88%	87.02%	55.58%
INVESTING ACTIVITIES
Capital Expenditures	$5.434M	$6.056M	$28.15M
YoY Change	-38.05%	-146.97%	-30.14%
Acquisitions			$0.00
YoY Change			-100.0%
Other Investing Activities	$355.0K	-$130.0K	$99.00K
YoY Change	211.4%	-107.62%	-95.24%
Cash From Investing Activities	-$5.079M	-$6.186M	-$28.05M
YoY Change	-41.34%	-44.7%	-29.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$0.00		$555.0M
YoY Change	-100.0%		21.67%
Cash From Financing Activities	-$761.0K	47.18M	$128.1M
YoY Change	-100.93%	-1753.84%	-1211.51%
NET CHANGE
Cash From Operating Activities	-$14.20M	-6.428M	-$65.50M
Cash From Investing Activities	-$5.079M	-6.186M	-$28.05M
Cash From Financing Activities	-$761.0K	47.18M	$128.1M
Net Change In Cash	-$20.06M	34.57M	$34.52M
YoY Change	-143.45%	-297.81%	-136.92%
FREE CASH FLOW
Cash From Operating Activities	-$14.20M	-$6.428M	-$65.50M
Capital Expenditures	$5.434M	$6.056M	$28.15M
Free Cash Flow	-$19.63M	-$12.48M	-$93.65M
YoY Change	-44.7%	-232.04%	13.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	us-gaap	Impairment Of Intangible Asset Indefinite Lived Excluding Goodwill Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2022#AssetImpairmentCharges
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	10040000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3204000	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	6755000	usd
CY2021Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	194133000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	143578000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	123690000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	139730000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	226092000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	256646000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	286458000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	608811000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	246582000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	411696000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2030000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2233000	usd
CY2022Q4	us-gaap	Assets Assets	1078985000	usd
CY2021Q4	us-gaap	Assets Assets	1562694000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12559000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15146000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	53672000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	64584000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	47676000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	49433000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	8167000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	531600000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	543799000	usd
CY2022Q4	ati	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	98000	usd
CY2021Q4	ati	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	4341000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2835000	usd
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	45360000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	18886000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	67459000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	218424000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	250597000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1834000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2301000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	890198000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1051187000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	ati	Temporary Equity Par Value Per Share TemporaryEquityParValuePerShare	0.0001
CY2022Q4	ati	Temporary Equity Par Value Per Share TemporaryEquityParValuePerShare	0.0001
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	1000000	shares
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	1000000	shares
CY2022Q4	ati	Temporary Equity Stated Value Per Share TemporaryEquityStatedValuePerShare	1108.34
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	200000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	200000	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	140340000	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	470000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	470000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	207500000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	198400000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	207400000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	197400000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	20000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	20000	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	80000.00	shares
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	30000.00	shares
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	146000	usd
CY2021Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	95000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1378696000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1351597000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4899000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	28000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1339511000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-847132000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	43958000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	504418000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	4489000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	7089000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	48447000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	511507000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1078985000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1562694000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	635671000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	627871000	usd
CY2020	ati	Rent Clinic Supplies Contract Labor And Other Operating Expenses RentClinicSuppliesContractLaborAndOtherOperatingExpenses	166144000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	486262000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-539734000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-980038000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4243000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-22595000	usd
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2022	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	42525000	usd
CY2021	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	175140000	usd
CY2020	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	usd
CY2022	ati	Gain Loss On Cash Settlement For Outstanding Preferred Stock GainLossOnCashSettlementForOutstandingPreferredStock	0	usd
CY2021	ati	Gain Loss On Cash Settlement For Outstanding Preferred Stock GainLossOnCashSettlementForOutstandingPreferredStock	-14037000	usd
CY2020	ati	Gain Loss On Cash Settlement For Outstanding Preferred Stock GainLossOnCashSettlementForOutstandingPreferredStock	0	usd
CY2022	ati	Interest Income Expense Nonoperating Net Excluding Redeemable Preferred Stock InterestIncomeExpenseNonoperatingNetExcludingRedeemablePreferredStock	-45278000	usd
CY2021	ati	Interest Income Expense Nonoperating Net Excluding Redeemable Preferred Stock InterestIncomeExpenseNonoperatingNetExcludingRedeemablePreferredStock	-46320000	usd
CY2020	ati	Interest Income Expense Nonoperating Net Excluding Redeemable Preferred Stock InterestIncomeExpenseNonoperatingNetExcludingRedeemablePreferredStock	-69291000	usd
CY2022	ati	Interest Expense On Redeemable Preferred Stock InterestExpenseOnRedeemablePreferredStock	0	usd
CY2021	ati	Interest Expense On Redeemable Preferred Stock InterestExpenseOnRedeemablePreferredStock	10087000	usd
CY2020	ati	Interest Expense On Redeemable Preferred Stock InterestExpenseOnRedeemablePreferredStock	19031000	usd
CY2022	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-541577000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-48530000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-70960000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-493047000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-782028000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-298000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-668000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3700000	usd
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	5073000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-492379000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-778328000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5371000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.51
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.69
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.51
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.69
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	203150000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	203150000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	165805000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	165805000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128286000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128286000	shares
CY2022	us-gaap	Profit Loss ProfitLoss	-493047000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-782028000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-298000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	4871000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	1935000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-582000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-488176000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-780093000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-880000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-668000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-3700000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	5073000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-487508000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-776393000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5953000	usd
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	904919000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-582000	usd
CY2020	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	4453000	usd
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	5073000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5371000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	901117000	usd
CY2021	ati	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	210105000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	300000000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	128453000	usd
CY2021	ati	Adjustments To Additional Paid In Capital Warrant Liability Recognized In Reverse Recapitalization AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityRecognizedInReverseRecapitalization	26936000	usd
CY2021	ati	Adjustment To Additional Paid In Capital Recognition Of Contingent Shares Liability AdjustmentToAdditionalPaidInCapitalRecognitionOfContingentSharesLiability	220500000	usd
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	95000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5754000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	1935000	usd
CY2021	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	6298000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3700000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-778328000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	511507000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7374000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	19725000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	51000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	4871000	usd
CY2022	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	1932000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-668000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-492379000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	48447000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-493047000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-782028000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-298000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	486262000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	962303000	usd
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	40590000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	37995000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	39700000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	13869000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	16369000	usd
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	16231000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-48573000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-71088000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1814000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	48253000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	45536000	usd
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	44526000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7374000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	5754000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1936000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2873000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3252000	usd
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4109000	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	3481000	usd
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	6335000	usd
CY2022	ati	Increase Decrease In Accrued Interest On Redeemable Preferred Stock IncreaseDecreaseInAccruedInterestOnRedeemablePreferredStock	0	usd
CY2021	ati	Increase Decrease In Accrued Interest On Redeemable Preferred Stock IncreaseDecreaseInAccruedInterestOnRedeemablePreferredStock	10087000	usd
CY2020	ati	Increase Decrease In Accrued Interest On Redeemable Preferred Stock IncreaseDecreaseInAccruedInterestOnRedeemablePreferredStock	19031000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2809000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-5534000	usd
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	ati	Gain Loss On Cash Settlement For Outstanding Preferred Stock GainLossOnCashSettlementForOutstandingPreferredStock	0	usd
CY2021	ati	Gain Loss On Cash Settlement For Outstanding Preferred Stock GainLossOnCashSettlementForOutstandingPreferredStock	-14037000	usd
CY2020	ati	Gain Loss On Cash Settlement For Outstanding Preferred Stock GainLossOnCashSettlementForOutstandingPreferredStock	0	usd
CY2022	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-9000	usd
CY2021	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	5189000	usd
CY2020	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-469000	usd
CY2022	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0	usd
CY2021	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0	usd
CY2020	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-3863000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4243000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-22595000	usd
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2022	ati	Change In Fair Value Of Contingent Common Share Liability ChangeInFairValueOfContingentCommonShareLiability	-42525000	usd
CY2021	ati	Change In Fair Value Of Contingent Common Share Liability ChangeInFairValueOfContingentCommonShareLiability	-175140000	usd
CY2020	ati	Change In Fair Value Of Contingent Common Share Liability ChangeInFairValueOfContingentCommonShareLiability	0	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12573000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10201000	usd
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	8167000	usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	144667000	usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3307000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5024000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6688000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4841000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-39000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	284000	usd
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-413000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-48000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1831000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	798000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	854000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-5288000	usd
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	9174000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-53628000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-50942000	usd
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-42819000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	28000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	861000	usd
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	5056000	usd
CY2022	ati	Increase Decrease In Medicare Accelerated And Advance Payment Funds IncreaseDecreaseInMedicareAcceleratedAndAdvancePaymentFunds	-12288000	usd
CY2021	ati	Increase Decrease In Medicare Accelerated And Advance Payment Funds IncreaseDecreaseInMedicareAcceleratedAndAdvancePaymentFunds	-12605000	usd
CY2020	ati	Increase Decrease In Medicare Accelerated And Advance Payment Funds IncreaseDecreaseInMedicareAcceleratedAndAdvancePaymentFunds	26732000	usd
CY2022	ati	Transaction Related Amount Due To Former Owners TransactionRelatedAmountDueToFormerOwners	0	usd
CY2021	ati	Transaction Related Amount Due To Former Owners TransactionRelatedAmountDueToFormerOwners	3611000	usd
CY2020	ati	Transaction Related Amount Due To Former Owners TransactionRelatedAmountDueToFormerOwners	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-65508000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42100000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	138604000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28147000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	40293000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21887000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1675000	usd
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	250000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	157000	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	223000	usd
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	328000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	4523000	usd
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2020	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	0	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-39889000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21809000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	500000000	usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	12952000	usd
CY2020	ati	Payment Of Debt Issuance Discount PaymentOfDebtIssuanceDiscount	0	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	456202000	usd
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	20333000	usd
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2020	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	48200000	usd
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	68750000	usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	usd
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	usd
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	68750000	usd
CY2022	ati	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	0	usd
CY2021	ati	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	229338000	usd
CY2020	ati	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	0	usd
CY2022	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	usd
CY2021	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	59000000	usd
CY2020	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	300000000	usd
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
CY2022	ati	Payment Of Stock Issuance Costs And Issuance Discounts PaymentOfStockIssuanceCostsAndIssuanceDiscounts	4935000	usd
CY2021	ati	Payment Of Stock Issuance Costs And Issuance Discounts PaymentOfStockIssuanceCostsAndIssuanceDiscounts	19233000	usd
CY2020	ati	Payment Of Stock Issuance Costs And Issuance Discounts PaymentOfStockIssuanceCostsAndIssuanceDiscounts	0	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	203000	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2020	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	51000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	128000	usd
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2022	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	1932000	usd
CY2021	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	6298000	usd
CY2020	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	4453000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	128079000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11523000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-12970000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	34523000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-93512000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	103825000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48616000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	142128000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38303000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83139000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48616000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	142128000	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	4871000	usd
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1935000	usd
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-582000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1660000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4177000	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3010000	usd
CY2022	ati	Warrant Liabilities Recognized Upon The Closing Of The Reverse Recapitalization WarrantLiabilitiesRecognizedUponTheClosingOfTheReverseRecapitalization	0	usd
CY2021	ati	Warrant Liabilities Recognized Upon The Closing Of The Reverse Recapitalization WarrantLiabilitiesRecognizedUponTheClosingOfTheReverseRecapitalization	26936000	usd
CY2020	ati	Warrant Liabilities Recognized Upon The Closing Of The Reverse Recapitalization WarrantLiabilitiesRecognizedUponTheClosingOfTheReverseRecapitalization	0	usd
CY2022	ati	Contingent Consideration Common Shares Liabilities Recognized Upon The Closing Of The Reverse Recapitalization ContingentConsiderationCommonSharesLiabilitiesRecognizedUponTheClosingOfTheReverseRecapitalization	0	usd
CY2021	ati	Contingent Consideration Common Shares Liabilities Recognized Upon The Closing Of The Reverse Recapitalization ContingentConsiderationCommonSharesLiabilitiesRecognizedUponTheClosingOfTheReverseRecapitalization	220500000	usd
CY2020	ati	Contingent Consideration Common Shares Liabilities Recognized Upon The Closing Of The Reverse Recapitalization ContingentConsiderationCommonSharesLiabilitiesRecognizedUponTheClosingOfTheReverseRecapitalization	0	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	128453000	usd
CY2020	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	41617000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	41937000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	58421000	usd
CY2022	us-gaap	Derivative Cash Received On Hedge DerivativeCashReceivedOnHedge	3497000	usd
CY2021	us-gaap	Derivative Cash Received On Hedge DerivativeCashReceivedOnHedge	0	usd
CY2020	us-gaap	Derivative Cash Received On Hedge DerivativeCashReceivedOnHedge	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	84000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	81000	usd
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-1098000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	Overview of the Company<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATI Physical Therapy, Inc., together with its subsidiaries (herein referred to as “we,” “the Company,” “ATI Physical Therapy” and “ATI”), is a nationally recognized healthcare company, specializing in outpatient rehabilitation and adjacent healthcare services. The Company provides outpatient physical therapy services under the name ATI Physical Therapy and, as of December 31, 2022, had 923 clinics (as well as 20 clinics under management service agreements) located in 25 states. The Company offers a variety of services within its clinics, including physical therapy to treat spine, shoulder, knee and neck injuries or pain; work injury rehabilitation services, including work conditioning and work hardening; hand therapy; and other specialized treatment services. The Company’s direct and indirect wholly-owned subsidiaries include, but are not limited to, Wilco Holdco, Inc., ATI Holdings Acquisition, Inc. and ATI Holdings, LLC.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021 (the “Closing Date”), a Business Combination transaction (the “Business Combination”) was finalized pursuant to the Agreement and Plan of Merger ("Merger Agreement"), dated February 21, 2021 between the operating company, Wilco Holdco, Inc. (“Wilco Holdco”), and Fortress Value Acquisition Corp. II (herein referred to as "FAII" and "FVAC"), a special purpose acquisition company. In connection with the closing of the Business Combination, the Company changed its name from Fortress Value Acquisition Corp. II to ATI Physical Therapy, Inc. The Company’s common stock is listed on the New York Stock Exchange ("NYSE") under the symbol “ATIP.”</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. generally accepted accounting principles ("GAAP"). Under </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this method of accounting, FAII is treated as the acquired company and Wilco Holdco is treated as the acquirer for financial statement reporting and accounting purposes. As a result, the historical operations of Wilco Holdco are deemed to be those of the Company. Therefore, the financial statements included in this report reflect (i) the historical operating results of Wilco Holdco prior to the Business Combination; (ii) the combined results of FAII and Wilco Holdco following the Business Combination on June 16, 2021; (iii) the assets and liabilities of Wilco Holdco at their historical cost; and (iv) the Company’s equity structure for all periods presented. The recapitalization of the number of shares of common stock attributable to the Business Combination is reflected retroactively to the earliest period presented and will be utilized for calculating earnings per share in all prior periods presented. No step-up basis of intangible assets or goodwill was recorded in the Business Combination consistent with the treatment of the transaction as a reverse recapitalization of Wilco Holdco, Inc. Refer to Note 3 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations and Divestitures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 and CARES Act</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The coronavirus ("COVID-19") pandemic in the United States resulted in changes to our operating environment. We continue to closely monitor the impact of COVID-19 on all aspects of our business, and our priorities remain protecting the health and safety of employees and patients, maximizing the availability of services to satisfy patient needs and improving the operational and financial stability of our business. While we expect the disruption caused by COVID-19 and resulting impacts to diminish over time, we cannot predict the length of such impacts, and if such impacts continue for an extended period, it could have a continued effect on the Company’s results of operations, financial condition and cash flows, which could be material.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was signed into law providing reimbursement, grants, waivers and other funds to assist health care providers during the COVID-19 pandemic. The Company has realized benefits under the CARES Act including, but not limited to, the following: </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In 2020, the Company received approximately $91.5 million of general distribution payments under the Provider Relief Fund. These payments have been recognized in other expense (income), net in the consolidated statements of operations throughout 2020 in a manner commensurate with the reporting and eligibility requirements issued by the U.S. Department of Health & Human Services ("HHS"). Based on the terms and conditions of the program, including reporting guidance issued by HHS in 2021, the Company believes that it has met the applicable terms and conditions. This includes, but is not limited to, the fact that the Company’s COVID-19 related expenses and lost revenues for the year ended December 31, 2020 exceeded the amount of funds received. To the extent that reporting requirements and terms and conditions are subsequently modified, it may affect the Company’s ability to comply and ability to retain the funds.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company applied for and obtained approval to receive $26.7 million of Medicare Accelerated and Advance Payment Program ("MAAPP") funds during the quarter ended June 30, 2020. During the years ended December 31, 2022 and 2021, the Company applied $12.3 million and $12.6 million in MAAPP funds against the outstanding liability, respectively. During the year ended December 31, 2021, the Company transferred $1.8 million in MAAPP funds as part of the divestiture of its Home Health Service line. During the quarter ended September 30, 2022, the Company met the required performance obligations and performed the remaining services related to the MAAPP funds. Therefore, the remaining funds were applied and repaid during the quarter ended September 30, 2022. As of December 31, 2022 and December 31, 2021, zero and $12.3 million of the funds are recorded in accrued expenses and other liabilities, respectively.</span></div><div style="margin-bottom:14pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company elected to defer depositing the employer portion of Social Security taxes for payments due from March 27, 2020 through December 31, 2020, interest-free and penalty-free. The Company repaid the remaining deferred payments during the fourth quarter of 2022. Related to these payments, as of December 31, 2022 and December 31, 2021, zero and $5.9 million is included in accrued expenses and other liabilities, respectively.</span></div>
CY2022Q4	us-gaap	Number Of Stores NumberOfStores	923	clinic
CY2022Q4	ati	Number Of Stores Under Management Service Agreements NumberOfStoresUnderManagementServiceAgreements	20	clinic
CY2022Q4	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	25	state
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-65500000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-539700000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-493000000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1339500000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The effect of any change in estimates will be recognized in the current period of the change.</span></div>
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	800000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentrations of business riskThe Company provides physical therapy services to a large number of patients who participate in government healthcare programs, resulting in a customer concentration relating to Medicare and Medicaid’s service reimbursement programs. The Company believes that the concentration of credit risk with respect to other patient accounts receivable is limited due to the large number of patients that make up the Company’s patient base and the dispersion across many different insurance companies, preferred provider organizations and individuals.
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1700000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2300000	usd
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3000000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1200000	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1000000	usd
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1000000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	635671000	usd
CY2021Q2	ati	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	136.7
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	207300000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	196600000	shares
CY2021Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	34137000	shares
CY2021Q2	ati	Stock Converted Reverse Recapitalization Shares StockConvertedReverseRecapitalizationShares	130300000	shares
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	30000000	shares
CY2021Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	12845000	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	207282000	shares
CY2021Q2	ati	Common Stock Shares Issued Vesting Shares CommonStockSharesIssuedVestingShares	8625000	shares
CY2021Q2	ati	Common Stock Shares Issued Restricted CommonStockSharesIssuedRestricted	2014000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	196643000	shares
CY2021Q2	ati	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	345036000	usd
CY2021Q2	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	89877000	usd
CY2021Q2	ati	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	25821000	usd
CY2021Q2	ati	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	229338000	usd
CY2021Q2	ati	Reverse Recapitalization Transaction Cost Offset Against Proceeds ReverseRecapitalizationTransactionCostOffsetAgainstProceeds	19233000	usd
CY2021Q2	ati	Proceeds From Reverse Recapitalization Transaction Net Of Transaction Cost ProceedsFromReverseRecapitalizationTransactionNetOfTransactionCost	210105000	usd
CY2021Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	300000000	usd
CY2021Q2	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	59000000	usd
CY2021	ati	Reverse Recapitalization Transaction Cost ReverseRecapitalizationTransactionCost	5543000	usd
CY2021	ati	Net Increase Decrease In Cash Related To Reverse Recapitalization NetIncreaseDecreaseInCashRelatedToReverseRecapitalization	-2473000	usd
CY2021	ati	Reverse Recapitalization Transaction Cost ReverseRecapitalizationTransactionCost	5500000	usd
CY2021	ati	Adjustments To Additional Paid In Capital Recapitalization Transaction Costs AdjustmentsToAdditionalPaidInCapitalRecapitalizationTransactionCosts	19200000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	627871000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	592253000	usd
CY2022	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	unit
CY2021Q4	us-gaap	Goodwill Goodwill	608811000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	318925000	usd
CY2022	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	236000	usd
CY2022	ati	Goodwill Held For Sale Reclassifications GoodwillHeldForSaleReclassifications	3192000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	286458000	usd
CY2021Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	726800000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	246582000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	411696000	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	726800000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	318900000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	352896000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	336135000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	229206000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	196405000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	123690000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	139730000	usd
CY2022	us-gaap	Depreciation Depreciation	39846000	usd
CY2021	us-gaap	Depreciation Depreciation	37537000	usd
CY2020	us-gaap	Depreciation Depreciation	39510000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	28949000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	27257000	usd
CY2022Q4	us-gaap	Health Care Organization Accounts Payable To Third Party Payor HealthCareOrganizationAccountsPayableToThirdPartyPayor	6117000	usd
CY2021Q4	us-gaap	Health Care Organization Accounts Payable To Third Party Payor HealthCareOrganizationAccountsPayableToThirdPartyPayor	4240000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5551000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5998000	usd
CY2022Q4	ati	Accrued Contract Labor Current AccruedContractLaborCurrent	4483000	usd
CY2021Q4	ati	Accrued Contract Labor Current AccruedContractLaborCurrent	2057000	usd
CY2022Q4	ati	Accrued Occupancy Costs Current AccruedOccupancyCostsCurrent	2410000	usd
CY2021Q4	ati	Accrued Occupancy Costs Current AccruedOccupancyCostsCurrent	1895000	usd
CY2022Q4	ati	Medicare Accelerated And Advance Payment Funds And Deferred Employer Social Security Tax Cares Act Current MedicareAcceleratedAndAdvancePaymentFundsAndDeferredEmployerSocialSecurityTaxCARESActCurrent	0	usd
CY2021Q4	ati	Medicare Accelerated And Advance Payment Funds And Deferred Employer Social Security Tax Cares Act Current MedicareAcceleratedAndAdvancePaymentFundsAndDeferredEmployerSocialSecurityTaxCARESActCurrent	18179000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	6162000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4958000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	53672000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	64584000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	11137000	usd
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1935000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	8944000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1147000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	531600000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	551966000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	8167000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	531600000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	543799000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-5500000	usd
CY2022Q1	ati	Proceeds From Issuance Of Temporary Equity And Warrants ProceedsFromIssuanceOfTemporaryEquityAndWarrants	165000000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	48200000	usd
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	80000.00	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	100000	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	1515000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.002
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	65941000	shares
CY2022	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	50000.00	shares
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	503481000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	551681000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	20081000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	531600000	usd
CY2022	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4900000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4600000	usd
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4700000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4933000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4634000	usd
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4726000	usd
CY2020	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-105000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.032
CY2022Q1	ati	Proceeds From Issuance Of Temporary Equity And Warrants ProceedsFromIssuanceOfTemporaryEquityAndWarrants	165000000	usd
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	200000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	200000	shares
CY2022Q1	ati	Proceeds From Issuance Of Temporary Equity And Warrants ProceedsFromIssuanceOfTemporaryEquityAndWarrants	165000000	usd
CY2022Q4	ati	Temporary Equity Stated Value Per Share TemporaryEquityStatedValuePerShare	1108.34
CY2022Q1	ati	Temporary Equity Number Of Directors Equity Holders Can Elect TemporaryEquityNumberOfDirectorsEquityHoldersCanElect	1	segment
CY2022Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	20333000	usd
CY2022Q1	ati	Class Of Warrant Or Right Unamortized Discount ClassOfWarrantOrRightUnamortizedDiscount	203000	usd
CY2022Q1	ati	Class Of Warrant Or Right Issuance Cost ClassOfWarrantOrRightIssuanceCost	405000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	19725000	usd
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q2	ati	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	136.7
CY2020	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	usd
CY2021	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	usd
CY2021	ati	Gain Loss On Cash Settlement For Outstanding Preferred Stock GainLossOnCashSettlementForOutstandingPreferredStock	-14000000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2022	ati	Class Of Warrant Or Right Exercise Period ClassOfWarrantOrRightExercisePeriod	P30D
CY2022	ati	Class Of Warrant Or Right Expiration Period ClassOfWarrantOrRightExpirationPeriod	P5Y
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	8310000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	-3439000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	490000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	1445000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	6000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	37000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	128000	usd
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	251000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	43000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	128000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	251000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-37634000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-60002000	usd
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	3514000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-10939000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-11086000	usd
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1700000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-48573000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-71088000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1814000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-48530000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-70960000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2065000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.090
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.083
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.625
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-113731000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-179128000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-694000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-16827000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.031
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-25814000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.030
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1248000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.378
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	5000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	34000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-2551000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.771
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	167000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	31595000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.058
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	35731000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	82304000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.042
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-981000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.297
CY2022	ati	Effective Income Tax Rate Reconciliation Interest Expense On Redeemable Preferred Stock EffectiveIncomeTaxRateReconciliationInterestExpenseOnRedeemablePreferredStock	0	usd
CY2022	ati	Effective Income Tax Rate Reconciliation Interest Expense On Redeemable Preferred Stock Percent EffectiveIncomeTaxRateReconciliationInterestExpenseOnRedeemablePreferredStockPercent	0
CY2021	ati	Effective Income Tax Rate Reconciliation Interest Expense On Redeemable Preferred Stock EffectiveIncomeTaxRateReconciliationInterestExpenseOnRedeemablePreferredStock	2118000	usd
CY2021	ati	Effective Income Tax Rate Reconciliation Interest Expense On Redeemable Preferred Stock Percent EffectiveIncomeTaxRateReconciliationInterestExpenseOnRedeemablePreferredStockPercent	-0.002
CY2020	ati	Effective Income Tax Rate Reconciliation Interest Expense On Redeemable Preferred Stock EffectiveIncomeTaxRateReconciliationInterestExpenseOnRedeemablePreferredStock	3997000	usd
CY2020	ati	Effective Income Tax Rate Reconciliation Interest Expense On Redeemable Preferred Stock Percent EffectiveIncomeTaxRateReconciliationInterestExpenseOnRedeemablePreferredStockPercent	-1.209
CY2022	ati	Effective Income Tax Reconciliation Change In Fair Value Of Warrant Liability And Contingent Common Shares Liability EffectiveIncomeTaxReconciliationChangeInFairValueOfWarrantLiabilityAndContingentCommonSharesLiability	-9821000	usd
CY2022	ati	Effective Income Tax Reconciliation Change In Fair Value Of Warrant Liability And Contingent Common Shares Liability Percent EffectiveIncomeTaxReconciliationChangeInFairValueOfWarrantLiabilityAndContingentCommonSharesLiabilityPercent	0.018
CY2021	ati	Effective Income Tax Reconciliation Change In Fair Value Of Warrant Liability And Contingent Common Shares Liability EffectiveIncomeTaxReconciliationChangeInFairValueOfWarrantLiabilityAndContingentCommonSharesLiability	-41524000	usd
CY2021	ati	Effective Income Tax Reconciliation Change In Fair Value Of Warrant Liability And Contingent Common Shares Liability Percent EffectiveIncomeTaxReconciliationChangeInFairValueOfWarrantLiabilityAndContingentCommonSharesLiabilityPercent	0.049
CY2020	ati	Effective Income Tax Reconciliation Change In Fair Value Of Warrant Liability And Contingent Common Shares Liability EffectiveIncomeTaxReconciliationChangeInFairValueOfWarrantLiabilityAndContingentCommonSharesLiability	0	usd
CY2020	ati	Effective Income Tax Reconciliation Change In Fair Value Of Warrant Liability And Contingent Common Shares Liability Percent EffectiveIncomeTaxReconciliationChangeInFairValueOfWarrantLiabilityAndContingentCommonSharesLiabilityPercent	0
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	59893000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.111
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	132447000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.155
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	0	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	189000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	3661000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.005
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1151000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.348
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-48530000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.090
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-70960000	usd
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.083
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2065000	usd
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.625
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	7112000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	10420000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	11828000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	12530000	usd
CY2022Q4	ati	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	64288000	usd
CY2021Q4	ati	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	74115000	usd
CY2022Q4	ati	Deferred Tax Assets Acquisition And Transaction Costs DeferredTaxAssetsAcquisitionAndTransactionCosts	3186000	usd
CY2021Q4	ati	Deferred Tax Assets Acquisition And Transaction Costs DeferredTaxAssetsAcquisitionAndTransactionCosts	3770000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	104419000	usd
CY2022Q4	ati	Deferred Tax Assets Interest Expense DeferredTaxAssetsInterestExpense	43323000	usd
CY2021Q4	ati	Deferred Tax Assets Interest Expense DeferredTaxAssetsInterestExpense	33163000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6335000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4798000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	240491000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	221100000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	89907000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58312000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	150584000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	162788000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	26251000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	26563000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	66445000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	114451000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	54360000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	63252000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	20039000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	22089000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2375000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	3892000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	169470000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	230247000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	18886000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	67459000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	3000000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3027000	usd
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2341000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	686000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	3027000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3027000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	69533000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	65555000	usd
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	67279000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	20951000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	20045000	usd
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	18689000	usd
CY2022	us-gaap	Lease Cost LeaseCost	90484000	usd
CY2021	us-gaap	Lease Cost LeaseCost	85600000	usd
CY2020	us-gaap	Lease Cost LeaseCost	85968000	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	2600000	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1200000	usd
CY2020	ati	Lessee Lease Termination Costs LesseeLeaseTerminationCosts	4300000	usd
CY2020	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-3900000	usd
CY2020	ati	Lessee Lease Termination Costs Other LesseeLeaseTerminationCostsOther	400000	usd
CY2021	ati	Payments For Lease Terminations PaymentsForLeaseTerminations	4600000	usd
CY2022	ati	Lease Modification Operating Lease Assets Additions LeaseModificationOperatingLeaseAssetsAdditions	13700000	usd
CY2022	ati	Lease Modification Operation Lease Liabilities Additions LeaseModificationOperationLeaseLiabilitiesAdditions	13700000	usd
CY2021	ati	Lease Modification Operation Lease Liabilities Additions LeaseModificationOperationLeaseLiabilitiesAdditions	18400000	usd
CY2021	ati	Lease Modification Operating Lease Assets Additions LeaseModificationOperatingLeaseAssetsAdditions	18400000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	72440000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	65678000	usd
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	61993000	usd
CY2022	ati	Payments For Lease Terminations PaymentsForLeaseTerminations	0	usd
CY2021	ati	Payments For Lease Terminations PaymentsForLeaseTerminations	4570000	usd
CY2020	ati	Payments For Lease Terminations PaymentsForLeaseTerminations	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9688000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	28759000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	14067000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y10M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	6.9
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	6.5
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	64066000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	61885000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	52459000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	46069000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	35108000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	68006000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	327593000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	61493000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	266100000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	47676000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	218424000	usd
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	7200000	usd
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2022Q4	ati	Loss Contingency Number Of Plaintiffs Who Filed Consolidated Amended Complaint LossContingencyNumberOfPlaintiffsWhoFiledConsolidatedAmendedComplaint	4	segment
CY2022	us-gaap	Profit Loss ProfitLoss	-493047000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-782028000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-298000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-668000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3700000	usd
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	5073000	usd
CY2022	ati	Temporary Equity Cumulative Dividend TemporaryEquityCumulativeDividend	17876000	usd
CY2021	ati	Temporary Equity Cumulative Dividend TemporaryEquityCumulativeDividend	0	usd
CY2020	ati	Temporary Equity Cumulative Dividend TemporaryEquityCumulativeDividend	0	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-510255000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-510255000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-778328000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-778328000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5371000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5371000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	203150000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	203150000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	165805000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	165805000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128286000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128286000	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.51
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.51
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.69
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.69
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25183000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12817000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares

Files In Submission

Name	View Source	Status
0001815849-23-000004-index-headers.html	Edgar Link	pending
0001815849-23-000004-index.html	Edgar Link	pending
0001815849-23-000004.txt	Edgar Link	pending
0001815849-23-000004-xbrl.zip	Edgar Link	pending
ati-20221231.htm	Edgar Link	pending
ati-20221231.xsd	Edgar Link	pending
ati-20221231_g1.jpg	Edgar Link	pending
ati-20221231_g2.jpg	Edgar Link	pending
ati-20221231_g3.jpg	Edgar Link	pending
exhibit101_tsafullyexecu.htm	Edgar Link	pending
exhibit101_tsafullyexecu001.jpg	Edgar Link	pending
exhibit101_tsafullyexecu002.jpg	Edgar Link	pending
exhibit101_tsafullyexecu003.jpg	Edgar Link	pending
exhibit101_tsafullyexecu004.jpg	Edgar Link	pending
exhibit101_tsafullyexecu005.jpg	Edgar Link	pending
exhibit101_tsafullyexecu006.jpg	Edgar Link	pending
exhibit101_tsafullyexecu007.jpg	Edgar Link	pending
exhibit101_tsafullyexecu008.jpg	Edgar Link	pending
exhibit101_tsafullyexecu009.jpg	Edgar Link	pending
exhibit101_tsafullyexecu010.jpg	Edgar Link	pending
exhibit101_tsafullyexecu011.jpg	Edgar Link	pending
exhibit101_tsafullyexecu012.jpg	Edgar Link	pending
ati-20221231_cal.xml	Edgar Link	unprocessable
ati-20221231_def.xml	Edgar Link	unprocessable
ati-20221231_lab.xml	Edgar Link	unprocessable
ati-20221231_pre.xml	Edgar Link	unprocessable
ati-20221231_htm.xml	Edgar Link	completed
exhibit101_tsafullyexecu013.jpg	Edgar Link	pending
exhibit101_tsafullyexecu014.jpg	Edgar Link	pending
exhibit101_tsafullyexecu015.jpg	Edgar Link	pending
exhibit101_tsafullyexecu016.jpg	Edgar Link	pending
exhibit101_tsafullyexecu017.jpg	Edgar Link	pending
exhibit101_tsafullyexecu018.jpg	Edgar Link	pending
exhibit101_tsafullyexecu019.jpg	Edgar Link	pending
exhibit101_tsafullyexecu020.jpg	Edgar Link	pending
exhibit101_tsafullyexecu021.jpg	Edgar Link	pending
exhibit101_tsafullyexecu022.jpg	Edgar Link	pending
exhibit101_tsafullyexecu023.jpg	Edgar Link	pending
exhibit101_tsafullyexecu024.jpg	Edgar Link	pending
exhibit101_tsafullyexecu025.jpg	Edgar Link	pending
exhibit101_tsafullyexecu026.jpg	Edgar Link	pending
exhibit101_tsafullyexecu027.jpg	Edgar Link	pending
exhibit101_tsafullyexecu028.jpg	Edgar Link	pending
exhibit101_tsafullyexecu029.jpg	Edgar Link	pending
exhibit101_tsafullyexecu030.jpg	Edgar Link	pending
exhibit101_tsafullyexecu031.jpg	Edgar Link	pending
exhibit101_tsafullyexecu032.jpg	Edgar Link	pending
exhibit101_tsafullyexecu033.jpg	Edgar Link	pending
exhibit101_tsafullyexecu034.jpg	Edgar Link	pending
exhibit101_tsafullyexecu035.jpg	Edgar Link	pending
exhibit101_tsafullyexecu036.jpg	Edgar Link	pending
exhibit101_tsafullyexecu037.jpg	Edgar Link	pending
exhibit101_tsafullyexecu038.jpg	Edgar Link	pending
exhibit101_tsafullyexecu039.jpg	Edgar Link	pending
exhibit101_tsafullyexecu040.jpg	Edgar Link	pending
exhibit101_tsafullyexecu041.jpg	Edgar Link	pending
exhibit101_tsafullyexecu042.jpg	Edgar Link	pending
exhibit101_tsafullyexecu043.jpg	Edgar Link	pending
exhibit101_tsafullyexecu044.jpg	Edgar Link	pending
exhibit101_tsafullyexecu045.jpg	Edgar Link	pending
exhibit101_tsafullyexecu046.jpg	Edgar Link	pending
exhibit101_tsafullyexecu047.jpg	Edgar Link	pending
exhibit101_tsafullyexecu048.jpg	Edgar Link	pending
exhibit101_tsafullyexecu049.jpg	Edgar Link	pending
exhibit101_tsafullyexecu050.jpg	Edgar Link	pending
exhibit101_tsafullyexecu051.jpg	Edgar Link	pending
exhibit101_tsafullyexecu052.jpg	Edgar Link	pending
exhibit101_tsafullyexecu053.jpg	Edgar Link	pending
exhibit101_tsafullyexecu054.jpg	Edgar Link	pending
exhibit101_tsafullyexecu055.jpg	Edgar Link	pending
exhibit101_tsafullyexecu056.jpg	Edgar Link	pending
exhibit101_tsafullyexecu057.jpg	Edgar Link	pending
exhibit101_tsafullyexecu058.jpg	Edgar Link	pending
exhibit101_tsafullyexecu059.jpg	Edgar Link	pending
exhibit101_tsafullyexecu060.jpg	Edgar Link	pending
exhibit101_tsafullyexecu061.jpg	Edgar Link	pending
exhibit101_tsafullyexecu062.jpg	Edgar Link	pending
exhibit101_tsafullyexecu063.jpg	Edgar Link	pending
exhibit101_tsafullyexecu064.jpg	Edgar Link	pending
exhibit101_tsafullyexecu065.jpg	Edgar Link	pending
exhibit101_tsafullyexecu066.jpg	Edgar Link	pending
exhibit101_tsafullyexecu067.jpg	Edgar Link	pending
exhibit101_tsafullyexecu068.jpg	Edgar Link	pending
exhibit101_tsafullyexecu069.jpg	Edgar Link	pending
exhibit101_tsafullyexecu070.jpg	Edgar Link	pending
exhibit101_tsafullyexecu071.jpg	Edgar Link	pending
exhibit101_tsafullyexecu072.jpg	Edgar Link	pending
exhibit101_tsafullyexecu073.jpg	Edgar Link	pending
exhibit101_tsafullyexecu074.jpg	Edgar Link	pending
exhibit101_tsafullyexecu075.jpg	Edgar Link	pending
exhibit101_tsafullyexecu076.jpg	Edgar Link	pending
exhibit101_tsafullyexecu077.jpg	Edgar Link	pending
exhibit101_tsafullyexecu078.jpg	Edgar Link	pending
exhibit101_tsafullyexecu079.jpg	Edgar Link	pending
exhibit101_tsafullyexecu080.jpg	Edgar Link	pending
exhibit101_tsafullyexecu081.jpg	Edgar Link	pending
exhibit101_tsafullyexecu082.jpg	Edgar Link	pending
exhibit101_tsafullyexecu083.jpg	Edgar Link	pending
exhibit101_tsafullyexecu084.jpg	Edgar Link	pending
exhibit101_tsafullyexecu085.jpg	Edgar Link	pending
exhibit101_tsafullyexecu086.jpg	Edgar Link	pending
exhibit101_tsafullyexecu087.jpg	Edgar Link	pending
exhibit101_tsafullyexecu088.jpg	Edgar Link	pending
exhibit101_tsafullyexecu089.jpg	Edgar Link	pending
exhibit101_tsafullyexecu090.jpg	Edgar Link	pending
exhibit101_tsafullyexecu091.jpg	Edgar Link	pending
exhibit101_tsafullyexecu092.jpg	Edgar Link	pending
exhibit101_tsafullyexecu093.jpg	Edgar Link	pending
exhibit101_tsafullyexecu094.jpg	Edgar Link	pending
exhibit101_tsafullyexecu095.jpg	Edgar Link	pending
exhibit101_tsafullyexecu096.jpg	Edgar Link	pending
exhibit101_tsafullyexecu097.jpg	Edgar Link	pending
exhibit101_tsafullyexecu098.jpg	Edgar Link	pending
exhibit101_tsafullyexecu099.jpg	Edgar Link	pending
exhibit101_tsafullyexecu100.jpg	Edgar Link	pending
exhibit101_tsafullyexecu101.jpg	Edgar Link	pending
exhibit101_tsafullyexecu102.jpg	Edgar Link	pending
exhibit101_tsafullyexecu103.jpg	Edgar Link	pending
exhibit231_q42022.htm	Edgar Link	pending
exhibit311_fy2022.htm	Edgar Link	pending
exhibit312_fy2022.htm	Edgar Link	pending
exhibit32_fy2022.htm	Edgar Link	pending
exhibit42_descriptionofsec.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATIP
ATI Physical Therapy, Inc. Stock $atip

2023 Q1 Form 10-K Financial Statement

#000181584923000004 Filed on March 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATIP ATI Physical Therapy, Inc. Stock $atip

2023 Q1 Form 10-K Financial Statement

#000181584923000004 Filed on March 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATIP
ATI Physical Therapy, Inc. Stock $atip